Development of an in vitro system to study heme-induced caspase activation
Project Number1R03AI178641-01
Contact PI/Project LeaderBOUCHIER-HAYES, LISA
Awardee OrganizationBAYLOR COLLEGE OF MEDICINE
Description
Abstract Text
PROJECT SUMMARY
Excessive intravascular hemolysis of red blood cells (RBCs) leads to numerous complications associated with
uncontrolled inflammation including pain, vaso-occlusion, and organ damage that underlie the pathophysiology
of several disease states including sepsis, intravascular hemorrhage, and sickle cell disease (SCD). The primary
mediator of this inflammation is heme released from damaged RBCs. The applicant’s goup recently reported
that heme activates the inflammatory caspases, caspase-1, caspase-4, and caspase-5 to coordinate the
cleavage and release of the apical pro-inflammatory cytokine IL-1β. Importantly, unlike caspase-1, caspase-4
and caspase-5 are activated independently of inflammasome assembly. Thus, heme is one of the first examples
of a DAMP (damage associated molecular pattern) that activates the non-canonical inflammasome pathway.
The applicant has shown that heme binds caspase-4 and caspase-5 and induces oligomerization of these
caspases. The central hypothesis is that heme directly binds to caspase-4 and caspase-5 to induce
oligomerization and activation. The hypothesis will be tested by the following Aims: 1) to determine the
biophysical composition of heme-induced inflammatory caspase complexes and 2) to identify the protein
components required for heme-induced inflammatory caspase activation. Under the first Aim full length
recombinant caspase proteins will be produced and the ability of heme to bind caspases and to induce caspase
oligomerization and cleavage will be assessed. Under the second aim the amino acid residues required for heme
binding, oligomerization and cleavage will be identified as well as the type of cytosolic factors, if any, contribute
heme-induced caspase activation. This work will provide an in vitro assay that will be the basis for future rational
drug design approaches and a source of purified caspases that can be used for future studies to determine the
structures of the heme-induced caspase complexes. Understanding the mechanisms of inflammatory caspase
activation with provide justification for targeting these proteins to improve clinical outcomes in hemolytic
conditions.
Public Health Relevance Statement
PROJECT NARRATIVE
Correct regulation of inflammatory caspases is critical for preventing uncontrolled inflammation in response to
hemolysis. The proposed research is relevant to public health because it will provide important mechanistic
insights into how inflammatory caspases are regulated by extracellular heme, a key pathophysiological feature
of several disease states. Thus, the proposed research is relevant to part of the mission of the National Institute
of Allergy and Infectious Diseases (NIAID) that pertains to understanding, treating, and preventing infectious and
immunologic diseases.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AlgorithmsAmino AcidsApicalBacteriaBindingBiological AssayBiophysicsCASP1 geneCASP5 geneCaspaseCatalytic DomainCellsClinicalCommunicable DiseasesComplexDataDevelopmentDimerizationDiseaseDrug DesignDrug ScreeningErythrocytesFunctional disorderFutureGenetic TranscriptionGoalsHemeHemolysisHemorrhageImmune System DiseasesIn VitroIncubatedIndividualInflammasomeInflammationInflammation MediatorsInflammatoryInflammatory ResponseInterleukin-1 betaLengthMeasuresMediatingMissionMolecularMultiprotein ComplexesMutateNational Institute of Allergy and Infectious DiseaseOrganOutcomePainPathway interactionsPatternPharmaceutical PreparationsPlant ExtractsProteinsPublic HealthRadiolabeledRecombinantsRegulationReportingResearchSepharoseSepsisSickle Cell AnemiaSite-Directed MutagenesisSourceStructureSystemTestingTranslatingWorkbiophysical propertiescandidate identificationcell typecofactorcytokineexperimental studyextracellularimprovedin vitro Assayinsightmonomerpreventreconstitutionresponsescale up
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
01-June-2023
Project End Date
31-May-2025
Budget Start Date
01-June-2023
Budget End Date
31-May-2024
Project Funding Information for 2023
Total Funding
$80,250
Direct Costs
$50,000
Indirect Costs
$30,250
Year
Funding IC
FY Total Cost by IC
2023
National Institute of Allergy and Infectious Diseases
$80,250
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R03AI178641-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03AI178641-01
Patents
No Patents information available for 1R03AI178641-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03AI178641-01
Clinical Studies
No Clinical Studies information available for 1R03AI178641-01
News and More
Related News Releases
No news release information available for 1R03AI178641-01
History
No Historical information available for 1R03AI178641-01
Similar Projects
No Similar Projects information available for 1R03AI178641-01